» Articles » PMID: 38746494

Long-term Follow-up in High-grade Meningioma and Outcome Analysis

Overview
Specialty Neurology
Date 2024 May 15
PMID 38746494
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: The determinants of progression-free survival (PFS) and overall survival (OS) for higher-grade meningiomas have not been clearly established and to summarize the long-term clinical outcome for patients with grade 2 or 3 meningioma and assess the PFS and OS factors.

Materials And Methods: The study included all individuals, who had undergone surgical removal of cerebral meningiomas between 2005 and 2020 and whose histological results suggested a World Health Organization (WHO) grade 2 or grade 3 diseases. Kaplan-Meier curves are plotted to examine tumor control and OS after the follow-up. The reverse Wald logistic regression and Mantel-Cox test were used in multivariate analysis for tumor recurrence and mortality.

Results: There were 94 individuals enrolled with 82 having WHO grade 2 tumors and 12 having WHO grade 3 lesions. Gross total resection of the tumor was present in 73 patients (78%), and adjuvant radiotherapy (RT) was administered to 43 (45.7%) individuals. During the course of the study, 17 patients died. The WHO grade of the tumor, the extent of resection, and the absence of bone involvement were all independent predictors of better survival in a multivariate analysis. Furthermore, whereas adjuvant RT after surgery enhanced survival, it was not statistically significant (hazard ratios [95% confidence interval CI] = 1.91 [0.15-23.52] [ = 0.61]).

Conclusion: The degree of tumor excision is the strongest predictor of PFS and OS. In the event of a recurrence, rather than opting for upfront radiation, a second surgery with the goal of maximum safe resection should be performed.

References
1.
Goldbrunner R, Stavrinou P, Jenkinson M, Sahm F, Mawrin C, Weber D . EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021; 23(11):1821-1834. PMC: 8563316. DOI: 10.1093/neuonc/noab150. View

2.
Nakamura M, Roser F, Michel J, Jacobs C, Samii M . Volumetric analysis of the growth rate of incompletely resected intracranial meningiomas. Zentralbl Neurochir. 2005; 66(1):17-23. DOI: 10.1055/s-2004-836225. View

3.
Saraf S, McCarthy B, Villano J . Update on meningiomas. Oncologist. 2011; 16(11):1604-13. PMC: 3233296. DOI: 10.1634/theoncologist.2011-0193. View

4.
Aizer A, Bi W, Kandola M, Lee E, Nayak L, Rinne M . Extent of resection and overall survival for patients with atypical and malignant meningioma. Cancer. 2015; 121(24):4376-81. DOI: 10.1002/cncr.29639. View

5.
Louis D, Perry A, Wesseling P, Brat D, Cree I, Figarella-Branger D . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8):1231-1251. PMC: 8328013. DOI: 10.1093/neuonc/noab106. View